Treatment with Yiqi Bushen Koufuye Combined with Chemotherapy for Preventing Postoperative Metastasis of Stomach Cancer — A Clinical Observation of 28 Cases

Jiang, Shen-jun; Tang-hong, Kuang; Yao, Yongwei; Yang, Jun; Wang, Yiqing

doi:10.1016/s0254-6272(09)60078-9

“…A summary of selected studies has been presented in Table 1 . Nine studies 14 - 22 were published in Chinese involving research in China, and one study 23 in English involved research in Japan. Two studies 20 , 21 in Chinese were Master’s theses.…”

Section: Resultsmentioning

confidence: 99%

“…Seven 15 , 17 - 20 , 22 , 23 out of a total of 10 studies were designed to compare the Bojungikki-tang administration group with no treatment group, and 2 studies 14 , 16 compared the Bojungikki-tang administration group with the Xuebao capsule (XBJ) administration group. In the one study, 21 Bojungikgi-tang and Diyushengbai tablets (DSP) were administered to the treatment group, and only DSP was administered to the control group before comparison.…”

Section: Resultsmentioning

confidence: 99%

“…Most studies were conducted within 2 to 20 weeks, but Okabe et al’s 23 study was conducted for approximately a year. Bojungikgi-tang in the form of a decoction was administered to the treatment group in 8 studies, 14 - 18 , 20 - 22 of which seven 14 - 18 ,20,22 administered the decoction twice per day, and only one study, 21 in combination with DSP, administered the decoction thrice per day. In these 2 studies, 19 , 23 Bojungikgi-tang granules (TJ-41) produced by Tsumura & Co. in Japan and Bojungikki-tang granules produced by Beijing Handian Pharmaceutical Co., Ltd. were administered 3 times a day.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Bojungikgi-tang for Chemotherapy-induced Leukopenia: A Systematic Review and Meta-Analysis

Ahn,

Park,

Choi

2024

Integr Cancer Ther

1

0

View full text Add to dashboard Cite

Chemotherapy-induced leukopenia is a common side effect of cytotoxic anticancer drugs. It can deprive patients of treatment opportunities, resulting in the delay, reduction, or discontinuation of chemotherapy or other anticancer drug administration. Two researchers searched English, Chinese, Japanese, and Korean electronic databases, without limiting the time period and language, using search terms such as “Bojungikgi,” “WBC,” “leuko,” and “neutrop.” Among the human randomized controlled studies in which Bojungikgi-tang was administered to patients who underwent chemotherapy, studies reporting leukopenia-related outcomes were selected, and data extraction, bias risk assessment, and meta-analysis were performed on the selected papers. Ten studies were selected, and a systematic review with meta-analysis was conducted. Nine papers were published in China and the total number of participants was 715. As a result of administering Bojungikgi-tang to these patients, the number of patients with chemotherapy-induced leukopenia significantly decreased (OR: 0.41, 95% CI: 0.27-0.61, P = .0001, I2 = 35%). Further, white blood cell counts were compared with that of the control group, and it showed an effect on prevention (MD: 0.64, 95% CI: 0.46-0.83, P < .00001, I2 = 90%). A pronounced effect was observed, especially when administered after a diagnosis based on the pattern identification, such as Qi deficiency. (OR: 0.32, 95% CI: 0.18-0.58, P = .0002, I2 = 0%). However, all studies had a high risk of bias due to non-blinding, and most studies had a high or uncertain risk of bias in creating random assignment orders and concealing them. Bojungikgi-tang has an effect on the prevention and treatment of chemotherapy-induced leukopenia. The effect rate can be increased when administered after proper diagnosis, and the possibility of adverse reactions and side effects is lower than that of Granulocyte-Colony Stimulating Factor (G-CSF) injection. Bojungikgi-tang appears to be useful in the treatment and prevention of leukopenia caused by cytotoxic anticancer drugs. However, it is necessary to conduct high-quality clinical studies in the future, considering the possibility of local and language bias, heterogeneity of carcinoma and intervention, and the risk of bias. Registration: PROSPERO CRD4202341054.

show abstract

“…The study also pointed out that traditional Chinese medicine can improve the activity of natural killer cells, macrophages, and lymphocytes. Liu et al [ 20 ] suggest that traditional Chinese medicine combined with chemotherapy can reduce the incidence of metastasis and recurrence in patients with gastric cancer within one year after the operation. Traditional Chinese medicine can improve the peripheral hemogram and immune function of patients with gastric cancer.…”

Section: Discussionmentioning

confidence: 99%

“…Still, there are differences in the 3-year survival rate [ 17 ]. Some studies have pointed out that traditional Chinese medicine cannot affect the effective rate of chemotherapy for gastric cancer [ 18 ], while some studies hold the opposite view [ 19 , 20 ]. Therefore, we conducted a meta-analysis to explore the effect of traditional Chinese medicine combined with chemotherapy on the efficacy and survival rate of chemotherapy, as well as the effects of adverse reactions in patients with gastric cancer.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Traditional Chinese Medicine Combined with Chemotherapy in the Treatment of Gastric Cancer: A Meta-analysis

Zhang¹,

Zhao

²

,

Liu

³

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Objective. Meta-analysis was conducted to explore the effects of CM combined with chemotherapy on the effective rate and survival rate of gastric cancer patients. Methods. Literature retrieval was performed in PubMed, MEDLINE, Embase, CENTRAL, and CNKI databases. The subject of the literature was to compare the efficacy of CM combined with chemotherapy and chemotherapy alone in patients with gastric cancer. According to the Cochrane manual, the risk of bias was assessed for inclusion in randomized controlled trials. The chi-square test was used for the heterogeneity test. Subgroup analysis and sensitivity analysis were used to explore the causes of heterogeneity. Funnel chart and Egger’s test were used to assess publication bias. Results. This study included 761 patients with gastric cancer from 10 literatures. The effective rate of chemotherapy in the CM combined group was higher than that in the chemotherapy alone group (odds ratio OR = 1.96 , 95% confidence interval (CI) (1.39, 2.78), Z = 3.81 , P = 0.0001 ), and there was no heterogeneity among studies ( ch i 2 = 5.68 , P = 0.68 , I 2 = 0 %). There was no significant publication bias among all studies ( P > 0.05 ). The one-year survival rate in the CM combined group was higher than that in the chemotherapy alone group ( OR = 3.25 , 95% CI (1.90, 5.54), Z = 4.32 , P < 0.0001 ). There was no heterogeneity among studies ( ch i 2 = 1.04 , P = 0.79 , I 2 = 0 %) and no significant publication bias among studies ( P > 0.05 ). The 3-year survival rate of gastric cancer patients in the traditional Chinese medicine combination group was higher than that in the chemotherapy alone group ( OR = 1.71 , 95% CI (1.06, 2.78), Z = 2.18 , P = 0.03 ). There was no heterogeneity among studies ( ch i 2 = 2.18 , P = 0.54 , I 2 = 0 %), and there was no significant publication bias ( P > 0.05 ). The incidence of nausea and vomiting after chemotherapy in gastric cancer patients in the Chinese medicine combination group was lower than that in the chemotherapy alone group ( OR = 0.47 , 95% CI (0.34, 0.64), Z = 4.80 , P < 0.00001 ). There was no heterogeneity among studies ( ch i 2 = 8.57 , P = 0.48 , I 2 = 0 %), and there was no significant publication bias ( P > 0.05 ). Conclusion. CM combined with chemotherapy can improve the effective rate and survival rate of gastric cancer and reduce the incidence of nausea and vomiting after chemotherapy. We recommend a large sample size, multicenter combined randomized controlled trial for validation.

show abstract

Use of Chinese herbal medicine therapies in comprehensive hospitals in central China: A parallel survey in cancer patients and clinicians

Chen

¹

,

Qiao

²

,

Ding

³

et al. 2015

J. Huazhong Univ. Sci. Technol. [Med. Sci.]

View full text Add to dashboard Cite

Chinese herbal medicine (CHM), as the largest application category of traditional Chinese medicine (TCM), is widely accepted among cancer patients in China. Herbal slice (HS) and Chinese patent drug (CPD) are commonly used CHM in China. This study aimed to investigate the utilization of CHM among clinicians and cancer patients in central China. Five hundred and twenty-five patients and 165 clinicians in 35 comprehensive hospitals in central China were asked to complete an anonymous questionnaire that was designed to evaluate the use of CHM. The results showed that 90.74% clinicians and 72.24% cancer patients used CHM during cancer treatment. The educational backgrounds of the clinicians and the age, education level, annual income, and cancer stage of the cancer patients were related to use of CHM. More than 90% clinicians and cancer patients had used CPD. Comparatively, the percentage of HS use was 10% lower than that of CPD use among clinicians and cancer patients. More clinicians preferred to use CHM after surgery than cancer patients did (20.41% vs. 5.37%). Enhancing physical fitness and improving performance status were regarded as the most potential effect of CHM on cancer treatment (85.71% among clinicians and 94.07% among cancer patients), in comparison with directly killing tumor cells (24.49% among clinicians and 31.36% among patients). As for refusal reasons, imprecise efficacy was the unanimous (100%) reason for clinicians' rejection of CHM, and 95.58% patients objected to using CHM also for this reason. Furthermore, the side effects of CHM were more concerned by clinicians than by patients (33.33% vs. 15.81%). In conclusion, our survey revealed that CHM was popularly accepted by clinicians and cancer patients in central China. The reasons of use and rejection of CHM were different between clinicians and cancer patients.

show abstract

Treatment with Yiqi Bushen Koufuye Combined with Chemotherapy for Preventing Postoperative Metastasis of Stomach Cancer — A Clinical Observation of 28 Cases

Cited by 7 publications

References 0 publications

Bojungikgi-tang for Chemotherapy-induced Leukopenia: A Systematic Review and Meta-Analysis

Bojungikgi-tang for Chemotherapy-induced Leukopenia: A Systematic Review and Meta-Analysis

Efficacy of Traditional Chinese Medicine Combined with Chemotherapy in the Treatment of Gastric Cancer: A Meta-analysis

Use of Chinese herbal medicine therapies in comprehensive hospitals in central China: A parallel survey in cancer patients and clinicians

Contact Info

Product

Resources

About